Sareh Keshavarzi
Overview
Explore the profile of Sareh Keshavarzi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
490
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ortega C, Anconina R, Joshi S, Metser U, Prica A, Johnson S, et al.
Nucl Med Commun
. 2024 Oct;
45(12):1039-1046.
PMID: 39412293
Purpose: The purposes was to build model incorporating PET + computed tomography (CT) radiomics features from baseline PET/CT + clinical parameters to predict outcomes in patients with non-Hodgkin lymphomas. Methods:...
2.
Genta S, Lajkosz K, Yee N, Spiliopoulou P, Heirali A, Hansen A, et al.
J Exp Clin Cancer Res
. 2023 Oct;
42(1):276.
PMID: 37865776
Background: Immune-checkpoint inhibitors (ICI) can lead to immune-related adverse events (irAEs) in a significant proportion of patients. The mechanisms underlying irAEs development are mostly unknown and might involve multiple immune...
3.
Remalante-Rayco P, Espiritu A, Daghistani Y, Chim T, Atenafu E, Keshavarzi S, et al.
Rheumatology (Oxford)
. 2023 Oct;
63(7):1980-1986.
PMID: 37792508
Objectives: The objectives of this study were to investigate the incidence of demyelinating disease (DD) among SpA patients and to identify risk factors that predict DD in this patient population....
4.
Ortega C, Eshet Y, Prica A, Anconina R, Johnson S, Constantini D, et al.
Cancers (Basel)
. 2023 Apr;
15(7).
PMID: 37046717
Purpose: The aim of the study is to evaluate the prognostic value of a joint evaluation of PET and CT radiomics combined with standard clinical parameters in patients with HL....
5.
Wong P, Masucci L, Florescu M, Plourde M, Panet-Raymond V, Pavic M, et al.
Neurooncol Adv
. 2023 Apr;
5(1):vdad018.
PMID: 37025758
Background: Anti-PD-1 has activity in brain metastases (BM). This phase II open labeled non-randomized single arm trial examined the safety and efficacy of combining nivolumab with radiosurgery (SRS) in the...
6.
Wong D, Luo P, Znassi N, Arteaga D, Gray D, Danesh A, et al.
Cancer Res Commun
. 2023 Mar;
3(2):267-280.
PMID: 36860651
Significance: Here, we demonstrate integrated, longitudinal cfDNA sequencing using multi-omic approaches is more effective than unimodal analysis. This approach supports the use of frequent blood testing using comprehensive genomic, fragmentomic,...
7.
Hussein H, Abbas E, Keshavarzi S, Fazelzad R, Bukhanov K, Kulkarni S, et al.
Radiology
. 2023 Jan;
306(3):e221785.
PMID: 36719288
Background The best supplemental breast cancer screening modality in women at average risk or intermediate risk for breast cancer with dense breast and negative mammogram remains to be determined. Purpose...
8.
Minich A, Arisar F, Shaikh N, Herman L, Azhie A, Orchanian-Cheff A, et al.
EClinicalMedicine
. 2022 Jul;
50:101534.
PMID: 35812989
Background: Non-alcoholic steatohepatitis (NASH) is the second-leading indication for liver transplantation (LT) worldwide and is projected to become the leading indication. Our study aimed to determine clinical variables that predict...
9.
Said B, Ailles L, Karamboulas C, Meens J, Huang S, Xu W, et al.
JAMA Otolaryngol Head Neck Surg
. 2022 Mar;
148(4):342-349.
PMID: 35238880
Importance: Patient-derived xenografts (PDXs) offer the opportunity to identify patients with oral cavity squamous cell carcinoma (OSCC) who are at risk for recurrence and optimize clinical decision-making. Objective: To develop...
10.
Brick R, Padgett L, Jones J, Wood K, Pergolotti M, Marshall T, et al.
J Cancer Surviv
. 2022 Feb;
17(6):1725-1750.
PMID: 35218521
Purpose: To characterize delivery features and explore effectiveness of telehealth-based cancer rehabilitation interventions that address disability in adult cancer survivors. Methods: A systematic review of electronic databases (CINAHL Plus, Cochrane...